BioView to develop lung cancer test with Clarient

The test, which examines the patient's sputum, was first developed at the M.D. Anderson Cancer Center at the University of Texas.

BioView Ltd. (TASE:BIOV) has concluded a cooperation agreement with Clarient Inc. (Nasdaq: CLRT) for the development of a non-invasive diagnostic test for the early detection of non-small cell lung cancer (NSCLC). The test, which examines the patient's sputum, was first developed at the M.D. Anderson Cancer Center at the University of Texas. The test is expected to be administered for the early detection of lung cancer in smokers and other at-risk groups.

According to the National Institute of Cancer of Cancer in the US, lung cancer has the highest mortality rate of any cancer with 250,000 people diagnosed with the condition every year in the US alone where there are 160,000 fatalities annually. NSCLC is the most prevalent type of lung cancer, representing 85% of cases of the disease.

Rehovot-based BioView's innovative test is performed by DNA biomarkers developed at the M.D. Anderson Center. The company owns the exclusive license to the test.

BioView's share was down 0.52% to NIS 1.15 in early afternoon trading today. He share of Clarient, which is based in Aliso Viejo, California, closed on Monday at $2.37, giving a market cap of $185.87 million.

Published by Globes [online], Israel business news - - on December 15, 2009

© Copyright of Globes Publisher Itonut (1983) Ltd. 2009

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Biolight jumps on strong Zacks recommendation

Zacks cites the company for its technology, products, and meeting its targets.

VBL Therapeutics raises $40m in revived Nasdaq IPO

After the fiasco of the failed IPO in August, the drug development company scaled down the offering.

Assuta Hospital Gov't plans taxing private hospitals

The tax is one of the recommendations of the Economic Arrangments bill.

Erez Vigodman Teva boosted by European drug recommendations

Teva's share jumped 4% in Tel Aviv, after climbing 4.9% on Wall Street.

Partner/Orange Partner launches smartphone medical services

The new services includes prescriptions, hospital referrals, and confirmation of illness.

Reuven Krupik Clal Biotech unit PolyHeal nears licensing deal

PolyHeal has signed an MOU with a European drug company for an exclusive global license.

Nasdaq Galmed jumps on FDA hepatitis drug approval

The FDA awarded Fast Track Designation to aramchol for the treatment of Non-Alcoholic Steato-Hepatitis.

artificial sweeteners Weizmann Inst: Sweeteners cause diabetes, obesity

A study found that artificial sweeteners adversely affect intestinal bacteria.

BioCancell share jumps on positive cancer trial results

The clinical trials demonstrated safety and effectiveness of the treatment on high-risk bladder cancer patients.

Trendlines Group set for Toronto IPO

The technological incubators company is raising C$9 at a company value of C$80 million, after money.

Reuven Krupik Clal Biotech sues Hyperion for $200m

Clal Biotechnology alleges Hyperion made "rash and ill-considered" decisions in the Andromeda affair.

pharmaceuticals Clal Biotech: No evidence of misconduct by us

Clal Biotech says documents it was shown by Hyperion do not indicate it committed any misconduct regarding Andromeda.

Soroka Hospital  picture: Eyal Yitzhar Visiting Israel’s wounded at Soroka

Soroka Medical Center in Beersheva, the Israeli hospital closest to Gaza, bears the medical brunt of Operation Protective Edge.

Twitter Facebook Linkedin RSS Newsletters גלובס